The US Food and Drug Administration (FDA) has approved Neffy, a nasal spray for treating severe allergic reactions in ...

Cash Position & Operating Runway: As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments ...

Q4 2024 Earnings Call Transcript March 20, 2025 ARS Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.52, ...

Epinephrine auto-injectors are the standard-of-care for anaphylaxis from severe allergic reactions. It is a proven technology which delivers epinephrine intramuscularly, thus more quickly and ...

Lawmakers took a step Wednesday to cap the out-of-pocket cost for epinephrine injectors and ensure Nebraska schools and licensed child care programs have policies to respond to allergic reactions.

Whether finding new treatments for schizophrenia or first-time ways to tackle bladder cancer, these companies are finding ...

Good day, and welcome to ARS Pharmaceuticals fourth quarter and full year 2024 financial results conference call. (Operator Instructions) As a reminder, this call is being recorded. I would now like ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

This past week, my Motion 518: Expanding Availability of Epinephrine Auto-Injectors was successfully passed in Alberta’s ...

A retired firefighter, Sen. Kelly Seyarto has advocated to be more involved in disaster management work. A new committee ...